Navigation Links
Anti-pain agent shrinks oral cancers, leaves healthy tissues alone
Date:7/23/2014

SAN ANTONIO (July 22, 2014) Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School of Medicine at The University of Texas Health Science Center at San Antonio found. The Health Science Center has claimed intellectual property on results of the study, which is described in the journal Oral Oncology.

Late diagnosis, low survival

Oral squamous cell carcinoma is the eighth most common cancer in the U.S. with 40,000 new cases and nearly 8,000 deaths reported annually. "These tumors develop primarily on the side of the tongue," said study first author Cara B. Gonzales, D.D.S., Ph.D., assistant professor of comprehensive dentistry and an investigator with the Cancer Therapy & Research Center at the UT Health Science Center at San Antonio. "Unfortunately, 60 percent of patients have large tumors before seeking help, and their five-year survival rate is as low as 30 percent."

Pain blocker and other properties

Capsazepine was developed to block TRPV1, a calcium channel found in pain-sensing neurons. When TRPV1 is activated, a "pain signal" is sent to the brain. Capsazepine may reduce oral cancer pain because it blocks tumor-secreted factors from stimulating TRPV1 on these neurons. Dr. Gonzales found that capsazepine also has anti-cancer activity that may be associated with its ability to increase oxidative damage in tumors. Enhanced oxidative stress leads to auto-destruction of tumor cells, the researchers theorize.

"Here's the beauty," Dr. Gonzales said. "Capsazepine kills cancers selectively, leaving normal tissues alone, and also acts on neurons to block pain, a desirable combination in a potential medication."

Hope for future: systemic administration

So far, only local administration of capsazepine, directly into the primary tumors, has been tested. But many patients with oral cancer have disease that has spread. "We would like to be able to deliver this therapy systemically to target metastatic disease," Dr. Gonzales said. "Our laboratory is working with the Center for Innovation in Drug Discovery, a partnership between the Health Science Center and UTSA, to develop novel drugs that are similar to capsazepine with improved efficacy for the purpose of systemic administration to treat tumors that are inaccessible to local injection or that have metastasized."

At-risk patients

Randal A. Otto, M.D., F.A.C.S., professor and chairman of the Department of Otolaryngology-Head & Neck Surgery in the School of Medicine, said: "These tumors, if identified and treated early, are definitely curable. Unfortunately, most patients present with advanced disease with the cancer involving critical structures. This markedly decreases the chance for cure and dramatically increases the risks associated with treatment. Anything that selectively attacks the tumor while not injuring the normal tissues can only help the patient."

Acknowledgments

This work is supported by American Cancer Society Mentored Research Scholar Grant MRSG-11-061-01-PCSM and in part by Clinical & Translational Science Award (CTSA) Grant UL1TR001120 and the National Cancer Institute P30 Grant CA054174 to the Cancer Therapy & Research Center at the UT Health Science Center at San Antonio.


'/>"/>

Contact: Will Sansom
sansom@uthscsa.edu
210-567-2579
University of Texas Health Science Center at San Antonio
Source:Eurekalert

Related medicine news :

1. Hematology Analyzers and Reagents Market Worth $3.13 Billion by 2019 - New Report by MarketsandMarkets
2. Tak Mak study in Cancer Cell maps decade of discovery to potential anticancer agent
3. Charitable Agents Launches Online Platform to Revolutionize Real Estate Transactions Through Commission-Based Donations
4. Boston Z Realty Expands Variety of Languages Spoken by Agents
5. Molecule regulates production of antibacterial agent used by immune cells
6. Tamoxifen-resistant breast cancer reversed when drug paired with anti-malaria agent
7. New tumor-targeting agent images and treats wide variety of cancers
8. ALTTO test of dual HER2 blockade finds single agent remains the gold standard
9. Water pipe smoking causes significant exposure to nicotine and cancer-causing agents
10. New agent may enhance effectiveness of radiotherapy
11. Danish social workers have become the moral agents of the state
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... 19, 2017 , ... DMG Productions, producers of the award ... an upcoming episode, slated to air fourth quarter 2017. Check your local listings ... a company committed to supporting dentistry using the most technologically advanced restorative materials ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... Curl Keeper® ... of NaturallyCurly.com® The Curl Leaders, Editors’ Choice 2017 Award for the second year in ... for hair stylists and curlies alike was voted Best Moisturizer for Type 2 Wavies ...
(Date:8/19/2017)... ... August 19, 2017 , ... “Congratulations! It's A Boy! God’s Gift: ... both their parents and God. “Congratulations! It's A Boy! God’s Gift: A Story of ... from Long Island, New York. , Published by Christian Faith Publishing, Dale Anthony and ...
(Date:8/18/2017)... NY (PRWEB) , ... August 18, 2017 , ... ... of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the ... available for individuals with hearing impairments and shares the latest innovations in hearing ...
(Date:8/18/2017)... VA (PRWEB) , ... August 18, 2017 , ... ... asset protection services and financial consultations to communities throughout the greater DC region, ... K9 with the goal of rescuing local animals and training them to be ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... Aug. 2, 2017 CaryRx, a next-generation full-service pharmacy, ... service for patients in the Washington D.C. ... pharmacy by providing delivery of medications through the convenience of ... delivery or delivered within one hour to any location in ... to bring this invaluable service to Washington D.C. ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
(Date:7/26/2017)... 2017  Radium Medical Aesthetics, a leading medical aesthetic clinic in ... by effectively addressing several skin conditions from the inside. ... and more fragile. The skin becomes more transparent due to the ... harmful UV rays from the sun contributes to aging skin, causing ... ...
Breaking Medicine Technology: